Logo

Products & Services: Mar 26, 2009

Mar 26, 2009
Premium

Pharma IQ will hold a conference next month on the use of oligonucleotides in drug development.

The event will include, among others, sessions on vector-derived RNAi as tools and therapeutics; gene silencing by the gymnotic delivery of oligos; microRNA silencing; and use of miRNAs as biomarkers.

Details about the conference can be found here.

Filed under

Gene Editing, Gene Silencing, & CRISPR
RNAi
Breaking News
The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.